Out-Smarting diabetes with glucose sensors

March 2005
Engineer (00137758);3/11/2005, Vol. 293 Issue 7670, p11
Reports on British researchers' development of hologram-based glucose sensors that diabetics can wear as contact lenses. Development of the technology based on interactive holograms that can be engineered to change wavelength, image, brightness or position in response to a range of biological, chemical and physical stimuli; Description of the technology by company director of Smart Holograms and inventor of the technology Professor Chris Lowe.


Related Articles

  • Biosensor can give diabetics a life without needle pricks.  // British Journal of Healthcare Computing;9/ 7/2012, p1 

    This article reports that researchers at the Fraunhofer Institute for Microelectronic Circuits and Systems (IMS) in Duisburg, Germany, have produced a biosensor that can measure glucose levels continuously using tissue fluids other than blood. Tom Zimmermann, business unit manager at IMS,...

  • No Blood Sample Needed in Diabetes Detection Instrument.  // Japanese Biotechnology & Medical Technology;Jun/Jul2001, Vol. 1 Issue 3, p20 

    Describes a device developed by a team at Toyama University that gauged glucose levels in diabetes detection tests from mucus swabbed from the mouth, eliminating any need for blood sampling. Features of the device; Effectiveness of the unit.

  • Progress Being Made on Artificial Pancreas.  // Diabetes Health;Sep2004, Vol. 13 Issue 9, p70 

    Deals with the progress made on the development of the implantable Physiologic Insulin Delivery artificial pancreas system. Results of evaluation of the system in several diabetics; Type of meal served to diabetics during the evaluation; Assessment of blood glucose.

  • Biosensors in contact lenses advancing to monitor IOP, diabetes. Harrison, Laird // Ophthalmology Times;Jan2017, Vol. 42 Issue 1, p12 

    The article reports on the advancement of contact lens biosensors that can monitor biomarkers in tear film for intraocular pressure (IOP) and diabetes mellitus and mentions the launch of the Triggerfish IOP-monitoring contact lenses from contact lens-based solutions provider Sensimed.

  • Plano Colored Contact Lens Reclassification Proposal. Shovlin, Joseph P. // Review of Optometry;11/15/2002 Supplement, Vol. 139, p6 

    Editorial. Comments on the reclassification of tinted contact lenses without prescription from a medical device category in the U.S. Accounts on the standards of hygiene and sterility included in the policy; Role of the Food and Drugs Administration in regulating contact; Details on the...

  • PRODUCT REVIEW.  // Review of Optometry;8/15/2003, Vol. 140 Issue 8, p97 

    Presents several products for optometrists. Availability of lenses from Rodenstock USA company; Addition of base curves from Essilor company; Introduction of Freshlook dimensions enhancing color contact lenses from CIBA Vision company. INSETS: What's New On The Web;OPHTHALMIC FRAMES.

  • A Critical Appraisal of the Continuous Glucose-Error Grid Analysis. Wentholt, Iris M.; Hoekstra, Joost B.; Devries, J. Hans // Diabetes Care;Aug2006, Vol. 29 Issue 8, p1805 

    OBJECTIVE -- There is no consensus on how to optimally assess the accuracy of continuous glucose sensors. We examined the continuous glucose--error grid analysis (CG-EGA) and compared it with classical accuracy assessment methods, using data from a previously reported study comparing two...

  • DIAGNOSIS AND MONITORING.  // Current Medical Literature: Diabetes;2004, Vol. 21 Issue 1, p11 

    Looks at the issue of lag time between the blood glucose level and the measured interstitial levels in type 1 diabetic patients. Relationship between venous and interstitial levels; Comparison of venous blood glucose measurement with the equivalent interstitial levels derived from a Minimed...

  • Clinical Use of Real-Time Continuous Glucose Monitoring. Battelino, Tadej; Bolinder, Jan // Current Diabetes Reviews;2008, Vol. 4 Issue 3, p218 

    Maintaining near-normal glycaemia in all patients with diabetes mellitus (DM) has become a standard and a well accepted recommendation. Unfortunately, most people with DM do not achieve this clinical goal because of marked glycaemic fluctuations and hypoglycaemia. Real-time continuous glucose...


Other Topics